Novartis Reports the Biomarker Data From P-I/II (FORTITUDE) Study of Del-Brax in FSHD

Why It Matters

Demonstrating biomarker improvement validates del‑brax’s mechanism and de‑risks the upcoming Phase III, potentially delivering the first disease‑modifying therapy for FSHD. Success would give Novartis a foothold in a high‑unmet‑need market with limited competition.

Key Takeaways

• Del-brax reduced KHDC1L (cDUX) biomarker in FSHD patients
• Creatine kinase levels fell, indicating decreased muscle damage
• Phase I/II met primary and key secondary endpoints
• Phase III will enroll ~200 patients to assess functional outcomes
• Success could position Novartis as leader in rare muscular dystrophy therapies

Pulse Analysis

Facioscapulohumeral muscular dystrophy (FSHD) remains one of the most prevalent hereditary muscle‑wasting disorders, affecting roughly 1 in 20,000 people worldwide. Patients experience progressive loss of skeletal muscle strength, leading to functional limitations and reduced quality of life. Existing treatments are largely supportive, creating a sizable therapeutic gap. Novartis’s entry into this space with delpacibart braxlosiran reflects a broader industry shift toward gene‑targeted approaches that aim to modify disease biology rather than merely manage symptoms.

The Phase I/II FORTITUDE biomarker cohort demonstrated that del‑brax achieved robust target engagement, as evidenced by significant reductions in KHDC1L (cDUX) expression—a transcription factor implicated in FSHD pathogenesis—and concomitant drops in serum creatine‑kinase, a proxy for muscle injury. These biomarker shifts suggest the drug is effectively interrupting the molecular cascade that drives muscle degeneration. Importantly, the trial met both its primary endpoint and a key secondary endpoint, reinforcing confidence in the dosing regimen (2 mg/kg Q6W) and safety profile, which are critical considerations for rare‑disease programs where patient populations are limited.

Looking ahead, the upcoming Phase III FORTITUDE‑3 study will enroll about 200 participants across the U.S. and Europe, focusing on functional readouts such as quantitative muscle testing and the 10‑meter walk/run test. Positive outcomes could translate into the first disease‑modifying therapy for FSHD, opening a new revenue stream for Novartis and setting a precedent for biomarker‑driven development in muscular dystrophies. Competitors are watching closely, as success would raise the bar for efficacy expectations and potentially accelerate similar programs across the rare‑disease landscape.